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Atherosclerotic cardiovascular disease is the leading
cause of death in insulin-resistant (type 2) diabetes.
Vascular endothelial dysfunction paves the way for
atherosclerosis through impaired nitric oxide avail-
ability, inflammation, and generation of superoxide.
Surprisingly, we show that ablation of the three
genes encoding isoforms of transcription factor
FoxO in endothelial cells prevents atherosclerosis
in low-density lipoprotein receptor knockout mice
by reversing these subphenotypes. Paradoxically,
the atheroprotective effect of FoxO deletion is asso-
ciated with a marked decrease of insulin-dependent
Akt phosphorylation in endothelial cells, owing to
reduced FoxO-dependent expression of the insulin
receptor adaptor proteins Irs1 and Irs2. These find-
ings support a model in which FoxO is the shared
effector of multiple atherogenic pathways in endo-
thelial cells. FoxO ablation lowers the threshold of
Akt activity required for protection from atheroscle-
rosis. The data demonstrate that FoxO inhibition in
endothelial cells has the potential to mediate wide-
ranging therapeutic benefits for diabetes-associated
cardiovascular disease.
INTRODUCTION
Treatment advances in type 2 diabetes have significantly cur-
tailed the prevalence, severity, and costs associated with its
microvascular complications (National Institute of Diabetes
and Digestive and Kidney Diseases, 2005). Disappointingly, pro-
gress in treating atherosclerotic macrovascular complications
lags behind, partly because—unlike microvascular disease—
their development appears to be impervious to glycemia control
(U.K. Prospective Diabetes Study Group, 1998). Indeed, con-
siderable epidemiological evidence indicates that insulin resis-372 Cell Metabolism 15, 372–381, March 7, 2012 ª2012 Elsevier Inc.tance can promote atherosclerosis independent of hypergly-
cemia (Despres et al., 1996). Endothelial dysfunction is the
bellwether of atherosclerosis. And a wealth of cellular studies
have shown that insulin acts in endothelial cells (ECs) to
generate nitric oxide (NO), prevent inflammation, inhibit reactive
oxygen species, and decrease monocyte recruitment (Du et al.,
2006; Kim et al., 2006; Kuboki et al., 2000). These findings are
borne out by the demonstration that insulin resistance caused
by genetic ablation of insulin receptor (InsR) predisposes to
endothelial dysfunction and aortic lipid accumulation in
Apoe/mice (Rask-Madsen et al., 2010), as does Akt1 ablation
(Fernandez-Hernando et al., 2007). Given the pleiotropic actions
of insulin, and the panoply of Akt substrates, it seems that the
antiatherogenic effects of Akt could be mediated by multiple
substrates.
FoxO transcription factors (encoded by Foxo1, Foxo3a, and
Foxo4) are Akt substrates that regulate metabolic pathways in
different tissues (Accili and Arden, 2004). In EC, FoxO1 and
FoxO3a repress transcription of endothelial nitric oxide synthase
(eNos) (Potente et al., 2005) and promote inducible Nos (iNos)
expression in response to oxidative stress, leading to generation
of peroxynitrite and endothelial dysfunction (Tanaka et al., 2009).
These observations suggest that FoxO mediates aspects of
endothelial dysfunction that are conducive to atherogenesis.
But a direct test of this hypothesis, and genetic analyses of phys-
iologically relevant FoxO substrates in vivo have not been con-
ducted thus far. Three factors have prevented rigorous insight
into this issue: the presence of three FoxO isoforms (FoxO1,
FoxO3a, and FoxO4) with overlapping functions in ECs; the
developmental role of FoxOs in angiogenesis (Kitamura et al.,
2007), which might be expected to thwart the successful gener-
ation of EC-specific gene deletions; and the pleiotropism of InsR
and Akt functions, which are unlikely to be relayed exclusively
through FoxOs.
Seeking to fill this gap in knowledge, we generated triple
mutant mice lacking FoxO1, FoxO3a, and FoxO4 in ECs and
demonstrate that the triple knockout largely prevents aortic
lesion development in mice lacking Ldl receptor (Ldlr), indicating
that FoxOs integrate Akt signals to mediate multiple actions of
insulin required for endothelial function.
Figure 1. Insulin Signaling in Aortae of WTD-Fed Ldlr–/– Mice
(A) Glucose tolerance tests.
(B and C) Representative oil red O staining of en face aorta preparations (B) and quantification of lesion area (C) (n = 3–4 for each genotype).
(D and E) Representative immunoblots (D) and quantification (E) of insulin signaling, eNOS, and Erk1/2 in aortae isolated 5 min after intravenous insulin injection
from mice fed standard diet (SD) or Western diet (WTD) for 6 weeks. We determined band intensity from three independent experiments.
(F–J) We carried out similar experiments in mice fed SD or WTD for 20 weeks.
Data indicate means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 versus chow.
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Western Diet Promotes Early-Onset Insulin Resistance
and FoxO Activation
We first interrogated changes in aortic FoxO activity during the
progression of atherosclerosis in Ldlr/ mice fed Western-
type diet (WTD) for various lengths of time. Six weeks of WTD
resulted in hyperglycemia, hyperinsulinemia, dyslipidemia (Fig-
ure 1A, see Table S1 online) and aortic lipid accumulation, as
detected by oil red O staining in Ldlr/ mice (Figures 1B and
1C). In aortae excised from WTD-fed Ldlr/ mice following
insulin stimulation, InsR, Akt, FoxO1, and FoxO3a phosphoryla-
tion were significantly lower than in chow-fed mice, while Erk
phosphorylation was enhanced. The ratio of phosphorylated
eNOS to total eNOS was also decreased (Figures 1D and 1E).
Irs1 and Irs2 protein levels tended to decrease. After 20 weeks
on WTD, metabolic abnormalities (Figure 1F, Table S1) and lipid
accumulation worsened considerably (Figures 1G and 1H) and
were associated with further reductions of Akt, eNOS, FoxO1,
and FoxO3a phosphorylation, as well as Irs1 and Irs2 levels
(Figures 1I and 1J). These data suggest that FoxO activation in
response to vascular insulin resistance occurs early in the path-Ceogenesis of atherosclerosis. To pinpoint mechanisms leading to
decreased FoxO1 phosphorylation, we performed experiments
in primary cultures of murine aortic EC. Incubation with LPS or
FFA inhibited insulin-induced Akt, eNOS (Kim et al., 2005), and
FoxO1 phosphorylation, increasing the latter’s nuclear localiza-
tion (Figures S1A–S1D) and indicating that FoxO1 activation
can occur in response to EC stress.
Mice Lacking FoxO in ECs Are Protected from Vascular
Dysfunction and Atherosclerosis
To probe the role of FoxO in atherosclerosis, we used Tie2-cre-
mediated recombination to generate mice lacking all FoxO iso-
forms in vascular ECs (henceforth, vascular endothelial cell
knockout, VECKO) (Paik et al., 2007). Genotyping and mRNA
analyses indicated successful recombination at the three loci
and a >96% reduction of the three mRNAs (data not shown),
and of FoxO1 and FoxO3a protein levels in aortic (Figure 2B),
cardiac, and lung ECs (data not shown). FoxO4 protein levels
were undetectable by western blot in control Ldlr/ mice, even
though mRNA studies indicated that the gene is transcribed.
We investigated the effects of FoxO ablation in ECs on vas-
cular function and atherosclerosis by generating double-mutantll Metabolism 15, 372–381, March 7, 2012 ª2012 Elsevier Inc. 373
Figure 2. Glucose Metabolism, Vascular Function,
and Atherosclerosis in VECKO; Ldlr–/– Mice
(A and B) Foxo1, Foxo3a, and Foxo4 mRNA (A) or FoxO1
and FoxO3a protein levels (B) in cultured aortic ECs from
VECKO and control mice.
(C and D) Glucose (C) and insulin tolerance tests (D) in
VECKO; Ldlr/ and Ldlr/ mice after 18–19 weeks on
WTD (n = 7–10).
(E and F) Acetylcholine- (E) and Na nitroprusside-induced
(F) vasorelaxation in femoral arteries from VECKO; Ldlr/
and Ldlr/ mice after 18 weeks on WTD (n = 5). Data
indicate means ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001
versus WT or Ldlr/.
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Following 18–20 weeks on WTD, VECKO; Ldlr/ and Ldlr/
controls had similar glucose tolerance, insulin sensitivity (Figures
2C and 2D), body weight, plasma insulin, total and HDL choles-
terol, triglyceride, and FFA levels (Table S2). These data indicate
that, unlike endothelial Irs2 ablation (Kubota et al., 2011), Foxo
ablation doesn’t affect systemic insulin sensitivity.
We didn’t detect differences in systolic blood pressure
before or after WTD (data not shown). But WTD-fed VECKO;
Ldlr/ mice showed enhanced eNOS-dependent arterial re-
laxation, with a 4.5-fold decrease in the EC50 of endothelial
NO-dependent vasodilatation in response to acetylcholine
(Ach) compared to Ldlr/ littermates (7.9 ± 1.6 versus 36 ±
6.3 nM, p = 0.003) (Figure 2E). In contrast, we detected no
differences in endothelium-independent vasodilatation in re-
sponse to Na nitroprusside (9.6 ± 2.3 versus 12 ± 3.9 nM in
VECKO; Ldlr/ versus Ldlr/) (Figure 2F). These data indicate374 Cell Metabolism 15, 372–381, March 7, 2012 ª2012 Elsevier Inc.that FoxO ablation increases NO-dependent
vasodilatation following WTD.
Multiple analyses consistently indicated a
striking decrease of atherosclerosis in VECKO;
Ldlr/ mice compared to Ldlr/ controls. Oil
red O staining of en face dissected aortae re-
vealed a 77% reduction in lesion area, with
comparable reductions in the aortic arch and
descending aorta (76% and 74%, respectively)
(Figures 3A and 3B). In addition, we detected
lower collagen content in thoracic and brachio-
cephalic aorta (Figure 3C). Plaques in the
thoracic aorta of Ldlr/ mice demonstrated
evidence of smooth muscle cell migration and
macrophage infiltration, as detected by immu-
nostaining with a-smooth muscle actin and
Mac-3, respectively (Figure 3D). In contrast,
VECKO; Ldlr/ mice showed little evidence
of either increased smooth muscle cells or
lesional macrophages (Figure 3D). In addition,
we detected lower Vcam1 immunoreactivity in
lesional endothelium of aortae from VECKO;
Ldlr/ mice (Figure 3E), consistent with re-
duced expression of cell adhesion molecules.
The number of coronary lesions decreased by
80% in VECKO; Ldlr/ mice (Figure 3F).
In view of the reported off-target recombina-
tion induced by Tie2-Cre in bone marrow(BM)-derived cells (Murdoch et al., 2007), we determined the
contribution of BM-derived cells to the observed phenotype.
Proteins levels of FoxO1 and FoxO3a were within normal range
in BM and peripheral blood mononuclear cells (Figures S2A
and S2B), as were Foxo1, Foxo3a, and Foxo4 mRNA levels in
peritoneal macrophages (Figure S2C). To rule out a contribution
from BM-derived cells to the observed atheroprotective pheno-
type, we carried out BM transplantation experiments. We trans-
ferred BM obtained from Ldlr/ mice into VECKO; Ldlr/ or
control Ldlr/ mice. After 14 weeks on WTD, VECKO; Ldlr/
mice that received BM from Ldlr/ mice showed substantial
reduction in total lesion area compared to Ldlr/ mice that
received heterologous BM from Ldlr/ mice (Figures S2D and
S2E). The extent of reduction was the same as in the experi-
ments in Figure 3. These results exclude potential involvement
of hematopoietic cells and macrophages in protecting VECKO;
Ldlr/ mice from atherosclerosis.
Figure 3. Aortic and Coronary Immunohistochemistry
(A and B) Representative en face oil red O staining (A) and quantification (B) of lesion area in total, aortic arch, and descending thoracic aortae in VECKO; Ldlr/
and Ldlr/ mice after 20 weeks WTD (n = 11–13).
(C) Histological analysis of the brachiocephalic and thoracic aorta with hematoxylin and eosin (HE) and Masson trichrome staining. Values indicate quantification
of atherosclerotic lesions and positive area as percentage of total area, respectively (n = 4).
(D) Immunostaining of thoracic aorta with a-smooth muscle actin and Mac-3 antibodies.
(E) Immunostaining of thoracic aorta with Vcam-1 antibody. Values indicate quantification of immunoreactive areas as percentage of total area (n = 4).
(F) Histological analysis of coronaries by HE staining. Values indicate plaque-positive coronaries as percentage of total coronaries scored in four independent
sections of each mouse (n = 8).
Data indicate means ± SEM.*p < 0.05, **p < 0.01, and ***p < 0.001 versus Ldlr/. Scale bars, 200 mm.
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exerts atheroprotective effects in Ldlr/ mice, independent of
plasma lipid or glucose levels, and in a BM-independent fashion.
The histopathology data suggest that pleiotropic mechanisms
account for this difference—including increased NO production
and decreased macrophage content in lesions. To clarify the
underlying mechanisms, we performed further experiments in
primary EC cultures.
Increased NO Production in ECs from VECKO Mice
Consistent with the increased Ach-induced (NO-dependent)
vascular relaxation, we saw a marked increase of eNos mRNA
and protein in VECKO aortic EC (Figures 4A–4C), aortic extracts
(Figures 4F and 4G), heart (Figures S3A–S3C), and cardiac EC
(Figures S3D and S3E). Relative amounts of eNos dimer,
a readout of functional eNos (Zou et al., 2002), were comparable
between groups (Figures 4D and 4E). Basal eNos phosphoryla-
tion on Ser1176 was increased (Figures 4B, 4C, 4F, and 4G),
while levels of insulin-induced phosphorylation were similar
between the two genotypes. As a result, the ratio of eNos phos-
phorylated on Ser1176 to total eNos decreased in aortic ECs and
whole aortae from VECKO mice (Figures 4B, 4C, 4F, and 4G).CeSimilar results were observed in whole heart and cardiac EC
(Figures S3B, S3C, S3E, and S3F). Basal NO production was
markedly higher in aortic (Figures 4H and 4I) and cardiac EC
(Figures S3G and S3H) from VECKOmice but was not stimulated
further by insulin. Pretreatment with the eNOS inhibitor L-NAME
inhibited insulin-stimulated NO production in aortic EC (Figures
4H and 4I), suggesting that increased NO production in VECKO
ECs is eNOS dependent.
Blunted Expression of Cell Adhesion Molecules
in VECKO ECs
Monocyte recruitment by activated EC promotes athero-
sclerosis and is prevented by insulin (Nigro et al., 2006). We
measured basal and LPS-induced levels of mRNA-encoding
adhesionmolecules. LPS-induced Icam1 and Vcam1 expression
was blunted in cells from VECKO mice (Figure 5A). To establish
a causal relationship between FoxO loss of function and Vcam or
Icam levels, we probed the ability of a FoxO1 gain-of-function
mutant to regulate these genes in primary cultures of human
aortic endothelial cells (HAECs). The constitutively active FoxO1
mutant lacking key phosphorylation sites, FoxO1-ADA (Nakae
et al., 2003), increased Icam1 and Vcam1 expression in all Metabolism 15, 372–381, March 7, 2012 ª2012 Elsevier Inc. 375
Figure 4. eNOS Expression and NO Production in Aortic ECs and Aorta
(A) eNos levels in cultured aortic ECs from VECKO and control mice (n = 4).
(B and C) Representative immunoblots (B) and quantification (C) of p-eNOS-S1176 and total eNOS in cultured aortic ECs from VECKO and control mice following
insulin treatment (n = 3). The loading control is shown in Figure 6A.
(D and E) Representative immunoblots (D) and quantification (E) of eNOS dimer and monomer in cultured aortic ECs from VECKO and control mice analyzed by
low-temperature SDS-PAGE immunoblotting (n = 4).
(F and G) Representative immunoblots (F) and quantification (G) of p-eNOS-S1176 and total eNOS in cultured aortic ECs from VECKO and control mice (n = 3).
The loading control of Akt is shown in Figure 6A. Scale bar, 200 mm.
(H and I) Insulin-stimulated NO production in cultured aortic ECs from VECKO and control mice pretreated with L-NAME (0.5 mM) or vehicle. NO production was
visualized by DAF2-DA fluorescence (H) and quantified in (I). Data indicate means ± SEM. AU, arbitrary mRNA units. *p < 0.05, **p < 0.01, and ***p < 0.001 versus
controls.
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functional consequences of these increases, we measured
monocyte adhesion to cultured HAEC. FoxO1-ADA expression
enhanced adhesion of THP-1 cells to HAEC, and neutralizing
antibodies to Icam1 and Vcam1 reversed this effect (Figures
S4C and S4D). To determine whether Icam1 and Vcam1 are
direct targets of FoxO1, we performed reporter gene and chro-
matin immunoprecipitation (ChIP) assays. FoxO1-ADA in-
creased expression of a reporter gene under the control of
ICAM1 and VCAM1 promoters in human umbilical vein EC,
whereas a DNA-binding-deficient FoxO1-ADA (FoxO1-ADA-
DBD) (Kitamura et al., 2005) did not (Figures S4E and S4F).
Furthermore, ChIP assays showed that FoxO1 binds to cis-
acting DNA elements in the ICAM1 and VCAM1 promoters in
intact chromatin isolated from HAEC (Figure S4G).
Reduced Inflammation and Reactive Oxygen Species
in VECKO Aortic ECs
iNos isaFoxO1 target thatpromotesgenerationof reactiveoxygen
species in response to oxidative stress in vascular endothelium
(Tanaka et al., 2009). Its expressionwasmarkedly blunted in aortic376 Cell Metabolism 15, 372–381, March 7, 2012 ª2012 Elsevier Inc.ECs from VECKOmice, as was expression of inflammatory cyto-
kines Mcp-1, IL-1b, and IL-6 (Figure 5A). LPS-induced Akt phos-
phorylation promotes Nf-kB activation through Ikk phosphoryla-
tion (Romashkova and Makarov, 1999; Salmeron et al., 1996)
and was likewise reduced in ECs from VECKO mice (Figure 5B).
Consistently, LPS-induced p105 degradation, IkBa phosphoryla-
tion, and Nf-kB-luciferase activity were attenuated (Figures 5B
and 5C). These data indicate thatFoxodeletion in ECs suppresses
inflammation, possibly via direct transcriptional regulation and/or
its ability to decrease NF-kB activity (Senokuchi et al., 2008).
Production of superoxide and ROS by ECs is proatherogenic
and can be brought about by oxidative stress (Du et al., 2006).
Although in later stages of atherosclerosis macrophages are
the main source of ROS, production of ROS can be demon-
strated in early atherosclerotic lesions prior to macrophage
recruitment (Napoli et al., 1997). Moreover, eNos overexpression
in ECs can cause eNos dysfunction, increase superoxide pro-
duction, and promote atherogenesis in Apoe/ mice (Ozaki
et al., 2002). We therefore asked whether the elevated basal
levels of eNos in aortic EC from VECKO mice affected ROS
production. ROS/peroxinitrite production by VECKO aortic ECs
Figure 5. Proinflammatory Cytokine Expression, NF-kB Signaling, and Oxidative Stress in Aortic or Lung ECs
(A) Time courses of Icam1, Vcam1, Mcp1, iNos, IL-1b, and IL-6 induction in aortic ECs from VECKO and control mice. Basal (without LPS stimulation) gene
expression in control cells is set to 1.
(B) Immunoblot analysis of lung ECs from VECKO and control mice following stimulation with LPS for the indicated times.
(C) NF-kB luciferase activity in lung ECs from VECKO and control mice transduced with adenovirus encoding Nf-kB-responsive luciferase reporter construct
followed by LPS stimulation (n = 4).
(D and E) Free cholesterol (FC)- and H2O2-stimulated reactive oxygen species (ROS) production in aortic ECs from VECKO and control mice visualized by
DAF2-DA fluorescence (D) and quantified from four independent wells in (E).
(F and G) H2O2-stimulated superoxide production in aortic ECs from VECKO and control mice visualized by DHE fluorescence (F) and quantified in (G).
(H) Expression of NADPH oxidase subunits in aortic ECs from VECKO and control mice (n = 4). Data indicate means ± SEM. AU = arbitrary mRNA units. *p < 0.05,
**p < 0.01, and ***p < 0.001 versus controls. Scale bar, 250 mm.
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lower than in controls (Figures 5D and 5E), as was H2O2-induced
superoxide generation (Figures 5F and 5G). In addition, mRNAs
encoding NADPH oxidase subunits p22phox, p67phox, and
gp91phox—whose activity is required for ROS generation—
were significantly decreased (Figure 5H). These data support
the view that increased eNos levels in VECKO mice are athero-
protective, and that the failure to induce iNos prevents ROS
generation. Thus, it’s likely that the increased sensitivity of
VECKO arteries to Ach-induced vasodilatation is secondary to
greater NO bioavailability.
Decreased Inflammatory and Oxidative Responses
in VECKO; Ldlr–/– Mice
We measured expression of a panel of inflammatory cytokines,
chemokines, adhesion proteins, and NADPH oxidase compo-
nents on RNA isolated from aortae of VECKO; Ldlr/ and
Ldlr/ mice. iNos and Vcam1 were significantly reduced inCeVECKO; Ldlr/ aortae compared to Ldlr/ controls (Fig-
ure S4H), as were IL-6 and NADPH oxidase subunits p22phox
and gp91phox. Icam1 expression tended to be lower in VECKO;
Ldlr/ aortae, but not significantly so. Vcam1 and iNos protein
levels were similarly reduced (Figures S4I and S4J). Aortic
TBARS content was significantly lower in VECKO; Ldlr/
compared to controls (Figure S4K), whereas plasma TBARS
concentrations were comparable (data not shown). Thus, FoxO
deletion in ECs reduced iNos and Vcam1, decreased inflamma-
tion, and curtailed focal oxidative stress in aortae. These obser-
vations indicate that, in addition to increasing NO production,
FoxO ablation exerts atheroprotective effects by dampening
oxidative stress, inflammation, and monocyte recruitment.
Delayed Cellular Senescence and Decreased Apoptosis
in ECs from VECKO Mice
Foxo can inhibit cellular proliferation by increasing expression of
cell-cycle inhibitors (Medema et al., 2000; Paik et al., 2007).ll Metabolism 15, 372–381, March 7, 2012 ª2012 Elsevier Inc. 377
Figure 6. Insulin Signaling in Aortic ECs of VECKO Mice
(A and B) Representative immunoblots (A) and quantification (B) of insulin signaling in cultured aortic ECs from VECKO following insulin treatment.
(C) Irs1, Irs2, and Igf1r expression in cultured aortic ECs from VECKO and control mice. AU, arbitrary mRNA units.
(D) Illustration of conserved putative FoxO-binding sequences (red) in the Irs1 promoter and primers used for amplification of regions A and B during ChIP. TSS,
transcription start site.
(E) ChIP assay of cultured aortic ECs using immunoprecipitation (IP) with rabbit IgG or antibody against FoxO1 and RNApolymerase (Pol) II. Size of predicted PCR
products sizes is 88 and 208 bp, respectively. The asterisk on the gel indicates a nonspecific band. Data indicate means ± SEM. *p < 0.05, **p < 0.01, and
***p < 0.001 versus controls.
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(Hayashi et al., 2006) and prevent apoptosis (Dimmeler et al.,
1997). Consistently, aortic ECs from VECKO mice proliferated
more rapidly (Figures S5A and S5B), and showed an 80%
decrease in cellular senescence (Figures S5A and S5C). Apo-
ptosis induced by Tnf-a, FFA, H2O2, 7-keto-cholesterol (7-KC),
or FC decreased on average by 50% in VECKO cells (Figure S5D)
and was associated with lower levels of proapoptotic Bim, p21,
and p53, and proangiogenic Spry2 than controls (Figure S5E).
Paradoxical Decrease of Akt Phosphorylation
in FoxO-Deficient Aortic ECs
The effects described so far are remarkably broad and suggest
that insulin sensitivity in FoxO-deficient ECs should be in-
creased. But when we characterized insulin signaling in aortic
ECs from VECKO mice, we found the opposite. Total levels
and insulin-induced tyrosine phosphorylation of the insulin
receptor were preserved. But expression of the main InsR
substrates, Irs1 and Irs2, was nearly undetectable (Figures 6A
and 6B). Consequently, insulin-stimulated Akt phosphorylation
on Ser473 and Thr308 and Erk phosphorylation were greatly
decreased (Figures 6A and 6B). Likewise, levels of Igf1R were
decreased, possibly contributing to the decrease in Akt and
Erk phosphorylation, since insulin receptor and Igf1R engage
in hybrid receptor formation in ECs (Chisalita and Arnqvist,
2004). To rule out artifacts occurring during EC isolation, we
also measured these parameters in vivo in whole aorta extracts,378 Cell Metabolism 15, 372–381, March 7, 2012 ª2012 Elsevier Inc.and detected decreases of Irs1 and Igf1R expression and atten-
uated insulin-induced Akt phosphorylation (Figures S6A and
S6B). The changes in whole aortae are not as marked as in
cultured ECs, reflecting the heterogeneous composition of this
tissue.
Irs2 is a known FoxO target (Ide et al., 2004), and single FoxO1
knockout in liver decreases its expression (Matsumoto et al.,
2007). The transcription factors that regulate Irs1 expression
are unknown (Kubota et al., 2011). Irs1mRNA levels were signif-
icantly decreased in aortic ECs from VECKO mice, as were Irs2
and Igf1R levels (Figure 6C). We investigated whether FoxO
binds to the Irs1 promoter. The mouse Irs1 promoter contains
three conserved forkhead DNA binding sites in two regions, A
and B (Figure 6D). ChIP analysis revealed that FoxO1 binds to
both regions in aortic ECs (Figure 6E). In cardiac microvascular
ECs from VECKO mice, the decrease of Irs1 was less marked
than in aortic ECs (Figures S6C and S6D), and ChIP analysis
showed that FoxO1 binds exclusively to region A (Figure S6E).
These data reveal that Irs1 is a FoxO target gene in aortic ECs.
DISCUSSION
Atherosclerotic macrovascular complications account for nearly
half of diabetes-related deaths and expenditures, and show an
indifferent response to available antihyperglycemic drugs (Caro
et al., 2002). In addition, regulatory requirements for registration
of new antidiabetic drugs in the U.S. and Europe have made it
Cell Metabolism
Triple Foxo Knockout in Vascular Endotheliumunlikely that further progress in diabetes treatment can be
divorced from advances in treating its cardiovascular comorbid-
ities (Joffe et al., 2010). This study advances our pathophysiolog-
ical understanding and potential therapeutic thinking on the
atherosclerotic complications of diabetes in two ways: it dis-
closes an unexpectedly broad role of FoxOs as mediators of
insulin action on NO biogenesis, inflammation, lesional macro-
phage content, and ROS or superoxide production. And it
provides a critical test of the hypothesis that treating endothelial
insulin resistance may be sufficient to reduce atherosclerosis.
The preventive effect of FoxO ablation on atherosclerosis
likely ensues from its ability to increase cell survival andNO avail-
ability, and dampen inflammation, chemotaxis, and superoxide
generation. The effect of FoxO on eNos has been reported
(Potente et al., 2005), but its pathophysiological consequences
on atherosclerosis were hardly predictable. In fact, eNos over-
expression has been shown to cause eNos dysfunction and
superoxide production in Apoe/mice, resulting in accelerated
atherosclerosis (Ozaki et al., 2002), while another study showed
reduced lesion formation (van Haperen et al., 2002). Our findings
indicate that eNos induction is beneficial in the context of FoxO
ablation, possibly because of FoxO’s dual role as repressor of
eNos transcription and activator of iNos transcription. In VECKO
mice, combined inhibition of iNos and NAPDH oxidase subunits
that are required for ROS production during oxidative stress
(Giacco and Brownlee, 2010; Tanaka et al., 2009) likely contrib-
utes to reduced superoxide production. Thus, any NO generated
in FoxO-deficient cells is unlikely to be used for ROS production.
Interestingly, expression of dominant-negative InsR in ECs of
transgenic mice increased NADPH oxidase expression and
superoxide production (Duncan et al., 2008), consistent with
a FoxO-dependent effect.
An additional component of the atheroprotective mechanism
of FoxO ablation is its anti-inflammatory effect, leading to
decreased NF-kB activity and Icam1 and Vcam1 expression.
The latter probably results from a combination of direct tran-
scriptional effects of FoxO, and decreased NF-kB, which has
been shown to modulate their expression (Neish et al., 1992).
Increased NO can also contribute to the anti-inflammatory
responses in VECKO EC by stabilizing the NF-kB/IkBa complex
(Peng et al., 1995). Furthermore, previous reports demonstrated
that Erk mediates MCP-1 and Vcam-1 expression in HUVEC
(Cho et al., 2002; Modur et al., 1996). Therefore, decreased Erk
phosphorylation in VECKO ECs can also contribute to attenuate
inflammatory responses.
The association of these subphenotypes with the cellular
effect of FoxO ablation on insulin signaling is most remarkable,
as it provides prima facie evidence of a healthy EC that is virtually
devoid of insulin signaling through Akt and FoxO. While pre-
vious genetic rescue experiments certainly pointed to this
conclusion—for example, in the rescue of Irs1/Irs2 double
mutants by FoxO1 ablation (Dong et al., 2008)—our findings
add a pathophysiological dimension to these observations by
demonstrating that Irs1 and Irs2 are FoxO targets. These find-
ings can be construed to suggest that Akt’s primary role is to
keep FoxO in check, a conclusion supported by the compensa-
tory increase in Akt activity observed in FoxO gain-of-function
experiments (Chen et al., 2010; Matsumoto et al., 2006). But
what is FoxO’s role, then? We can extrapolate from work onCepancreatic b cells to propose that FoxO provides acute, but
not chronic, reprieve from metabolic stress (Kitamura et al.,
2005). Thus, insulin signaling through FoxO could be viewed
evolutionally as an acute stress response that goes awry when
inciting factors (hyperglycemia, dyslipidemia, or inflammation)
become entrenched. Physiologically, the likeliest role of this
mechanism is to fine-tune insulin signaling, buffering ECs against
fluctuating plasma insulin levels. This interpretation is consistent
with the fact that, while triple Foxo ablation is atheroprotective,
FoxO1 activation by glucose, cytokines, or FFA increases iNos
production and ROS/superoxide generation, indicating that the
three FoxOx are likely responsible for accelerated atheroscle-
rosis in mice lacking InsR (Rask-Madsen et al., 2010) or Akt1
(Fernandez-Hernando et al., 2007), as well as for endothelial
dysfunction elicited by oxidative stress (Duncan et al., 2008;
Vicent et al., 2003).
Our findings are also consistent with and expand the conclu-
sions reached in studies of Irs2 EC-specific knockouts (Kubota
et al., 2011). These workers proposed that reduced insulin-
induced eNOS phosphorylation in EC-specific Irs2/ mice
causes insulin resistance via impaired capillary recruitment in
skeletal muscle. In VECKO mice, Irs1 and Irs2 expression
decreases, but eNOS expression is increased. The increase in
total eNos levels offsets the decrease in Akt-induced eNos phos-
phorylation and likely allows FoxO-deficient ECs to maintain
elevated levels of NO production. The phosphor-eNos to total
eNOS ratio is 60% lower in VECKO ECs than in controls, possibly
due to reduced Akt activity. But actual NO production is
increased, reflecting absolute levels of phosphorylated eNos,
rather than phosphor-eNos/eNOS ratios. These data indicate
that the biological outcome—NO production—depends on
absolute phosphor-eNOS levels, not on the ratio of phosphory-
lated to total eNos (Fulton et al., 1999). Thus, we propose that
the increase of eNOS in ECs from VECKO mice protects them
from systemic insulin resistance by increasing NO production,
despite decreased Irs1 and Irs2 expression. Whether the in-
crease in NO generation has additional local effects on insulin
signaling in other tissues (e.g., liver, pancreatic islets, CNS) is
a question of paramount interest that will be addressed system-
atically in future studies.
In conclusion, we demonstrate a remarkable atheroprotective
effect of FoxO inhibition in mouse ECs, and identify endothelial
FoxO as a potential target for atherosclerosis prevention and
treatment.
EXPERIMENTAL PROCEDURES
Additional details of the Experimental Procedures are included in the
Supplemental Information.
Animals
Foxo1F/F3F/F4F/F mice have been described (Haeusler et al., 2010; Paik et al.,
2007). We generated vascular EC-specific triple FoxOs knockout mice
(VECKO) by mating Foxo1F/F3F/F4F/F mice with Tie2-Cre male mice (Kisanuki
et al., 2001) to avoid nonspecific deletion of floxed alleles by germline activa-
tion (de Lange et al., 2008). We then crossed VECKO and Ldlr/ mice to
generate VECKO:Ldlr/ mice. Atherosclerosis was induced by WTD (0.2%
cholesterol, 42% from fat-adjusted calorie diet, TD 88137, Harlan Tekland)
for indicated periods. All experiments were conducted using only male
Cre(+) mice and littermate Cre(–) (control) mice. The Columbia University
Animal Care and Utilization Committee approved all procedures.ll Metabolism 15, 372–381, March 7, 2012 ª2012 Elsevier Inc. 379
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Aortic EC isolation and culture were performed according to protocols as
described previously with some modifications (Harja et al., 2008; Kevil and
Bullard, 2001; Kobayashi et al., 2005; Rask-Madsen et al., 2010). Cardiac
and lung microvascular EC isolation and culture were performed as described
(Rask-Madsen et al., 2010).
Metabolic Analysis
We measured blood glucose with a glucometer (One Touch Ultra, Lifescan),
plasma insulin by ELISA (Millipore), triglyceride (Cayman chemical), choles-
terol, and nonesterified fatty acids by colorimetric assays (Cholesterol E and
NEFA C, Wako Pure Chemicals). Intraperitoneal glucose (1 g kg1) and insulin
(1 U kg1) tolerance tests were performed as described (Nakae et al., 2002).
Atherosclerotic Lesion Analysis
Aortas were pinned on silicon dishes and stained for lipids using oil
red O. Areas were quantified using ImageJ software and expressed as the
percentage of the total aorta area. Hearts were isolated and fixed in phos-
phate-buffered formalin and then dehydrated and embedded in paraffin.
Statistical Analysis
Comparisons were made using paired or unpaired t test, as appropriate. Bon-
ferroni post hoc tests were utilized. Results are presented as means ± SEM or
95% CI as appropriate. p < 0.05 was considered statistically significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, two tables, Supplemental
Experimental Procedures, and Supplemental References and can be found
with this article online at doi:10.1016/j.cmet.2012.01.018.
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